Technology | May 02, 2012

Spectranetics Receives FDA Approval for Advanced GlideLight Laser Sheath

May 2, 2012 — The Spectranetics Corp. announced U.S. Food and Drug Administration (FDA) approval of the new advanced GlideLight Laser Sheath for removal of cardiac leads. As part of the company’s vision to safely manage every lead, GlideLight delivers more precise control to reduce the force for safe lead extraction.

Spectranetics’ current laser sheath, the SLS II, requires significantly less force to advance than mechanical telescoping sheaths. GlideLight is a major leap forward, requiring 55 percent less force to advance than SLS II.

“Mechanical force is a leading cause of complications during lead extraction,” said Bruce Wilkoff, director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic and a nonpaid member of Spectranetics’ Medical Advisory Board. “[R]educed force improves the control for safely removing leads. It is particularly important to have control when breaking up tough binding sites.”

“GlideLight has taken us to the next level in lead extraction,” said Charles Kennergren, professor at Sahlgrenska University Hospital in Gothenburg, Sweden, and the first physician to use GlideLight clinically. “I am very impressed with the reduced force and increased control and efficiency that GlideLight has provided me.”

A limited market release of GlideLight will be conducted to gain early experience prior to a broader controlled launch. GlideLight will be the company’s focus at the Heart Rhythm Society meeting in Boston May 9-11.

For more information: www.spectranetics.com

Related Content

LivaNova Enters Binding Letter of Intent to Sell Cardiac Rhythm Management Business
News | EP Lab | January 26, 2018
January 26, 2018 — LivaNova PLC and MicroPort Scientific Corp.
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab | October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab | October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab | September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab | September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab | August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab | July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab | June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Videos | EP Lab | May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Videos | EP Lab | May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Overlay Init